Feb 11: The Medical Device Sector in India suffers from a considerable cost of manufacturing disability vis-à-vis competing economies, inter alia, on account of lack of adequate infrastructure, domestic supply chain and logistics, high cost of finance, inadequate availability of power, limited design capabilities, low focus on research and development (R&D) and skill development etc.
With an objective to boost domestic manufacturing, attract large investment in Medical Device Sector, the Department of Pharmaceuticals had launched a Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Medical Devices to ensure a level playing field for the domestic manufacturers of medical devices with a total financial outlay of Rs.3,420 cr. for the period 2020-21 to 2027-28.
The applications under four different Target Segments including “Cancer care/Radiotherapy Medical Devices”, “Radiology & Imaging Medical Devices (both ionizing & non-ionizing radiation products) and Nuclear Imaging Devices”, “Anaesthetics & Cardio-Respiratory Medical Devices including Catheters of Cardio-Respiratory Category & Renal Care Medical Devices” and “All Implants including Implantable Electronic Devices” were invited.
The Government has approved applications of following applicants, which fulfill the prescribed laid down criteria, as under:
|Name of approved Applicant||Name of Eligible Product||CommittedInvestment(in Rs. crores)|
|M/s Siemens Healthcare Private Limited||CT Scan and MRI||91.91|
|M/s Allengers Medical Systems Limited (AMSL)||CT Scan, MRI, Ultrasonography, X-Ray, Cath Lab,Positron Emission Tomography (PET) Systems,Single Photon EmissionTomography (SPECT),Mammography and C arm.||50.00|
|M/s Allengers OEM PrivateLimited (AOPL)||X Ray Tubes, Collimators, Flat Panel Detector andMonitors’||40.00|
|M/s Wipro GE Healthcare Private Limited (WGHPL)||‘CT Scan’, ‘Cath Lab’ and ‘Ultrasonography’||50.22|
|M/s Nipro India CorporationPrivate Limited (NICPL)||‘Dialyzer’||180.00|
|M/s Wipro GE HealthcarePrivate Limited (WGHPL)||‘Anaesthesia Unit Ventilator’ and ‘Patient Monitor’||53.86|
|M/s Sahajanand Medical Technologies Private Limited (SMTPL)||‘Heart Valves’, ‘Stents’, ‘PTCA Balloon Dilatation Catheter’ and ‘Heart Occluders’||166.89|
|M/s Innvolution HealthcarePrivate Limited (IHPL)||‘Stents’ and ‘PTCA Balloon Dilation Catheter’||21.75|
|M/s Integris Health PrivateLimited (IHPL) for Eligible Products||Transcatheter Aortic HeartValve||75.00|
The setting up of these plants will lead to a total committed investment of Rs. 729.63 crore by the companies and employment generation of about 2,304. The commercial production is projected to commence from 1st April, 2022 and the disbursal of production linked incentive by the Government over the five years period would be up to a maximum of Rs.121.00 crore per applicant per target segment. The setting of these plants will make the country self-reliant to a large extent in the specified target segments in the Medical Devices Sector. The remaining pending applications are proposed to be taken up for approval by end of February, 2021.